卡培他滨化疗同步放射治疗局部晚期直肠癌的疗效观察

目的 观察卡培他滨(希罗达)化疗同步放射治疗(放疗)局部晚期直肠癌的有效性和安全性.方法 选择22例晚期直肠癌患者,均给予卡培他滨1 300 mg·m-2·d-1,分2次口服.从放疗的第1天开始,连续用2周,然后休息1周为1个周期,放疗期间化疗2个周期.与化疗同步进行全盆腔放疗,体外照射总剂量为60～68 Gy/30～35次.结果 22例患者治疗后完全缓解3例(13.6%),部分缓解13例(59.1%),稳定2例(9.1%),进展4例(18.2%),有效率为72.7%.1年局部控制率为68.2%(15/22),1年生存率为81.8%(18/22),2年生存率为50.0%(11/22).主要毒性反应是大便次数增多和骨髓抑制.结论 卡培他滨化疗同步放疗局部晚期直肠癌的效果好,且患者可以耐受毒性反应.

Capecitabine Chemotherapy Concurrent with Radiotherapy for Patients with Locally Advanced Rectal Cancer

Objective To evaluate the efficacy and safety of Capecitabine chemotherapy concurrent with radiotherapy in patients with locally advanced rectal cancer.Methods Twenty-two patients with advanced rectal cancer were given Capecitabine (Xeloda) 1 300 mg·m-2·d-1 orally,twice a day,for two continuous weeks,and then with one week rest,which was a course.This was done twice during the period of radiotherapy.Concomitant radiotherapy to the whole pelvic area was external irradiation TD,and total dose of TD was 60-68 Gy/30-35 F.Results After treatment,among the 22 patients,there 3 (13.6%) reached complete response (CR),13 (59.1%) partial response (PR),2 (9.1%) stable disease (SD),and 4 (18.2%) progressed disease (PD),with a total response rate of 72.7%.One-year local control rate was 68.2% (15/22),one-year survival rate was 81.8% (18/22),and 2-year survival rate was 50% (11/22).The main toxicity were radiation proctitis and bone marrow suppressionConclusion The Capecitabine chemotherapy concurrent with radiotherapy has a better efficacy for locally advanced rectal cancer,and its toxicity is tolerable by the patient.